Botulinum toxin formulations like Botox, Dysport and Xeomin are globally used - but their legal status and regulatory pathways differ significantly across regions

In the United States, BoNT products are regulated as biologics under the FDA’s Biologics License Application system.
Approved products include onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, and newer entrants like prabotulinumtoxinA and daxibotulinumtoxinA.
All require strict clinical trials and post-market surveillance.

Australia regulates BoNT through the Therapeutic Goods Administration.
Only approved prescription formulations can be administered by licensed professionals, and enforcement against unauthorized cosmetic injections is strict due to safety concerns.

In Europe, approval is centralized through the European Medicines Agency, but pricing and reimbursement are controlled by individual countries.
This creates a dual system - scientific approval is unified, but market access varies widely.
Cost containment policies are accelerating biosimilar interest in several EU markets.

In Canada, Health Canada regulates botulinum toxin products as prescription biologics.
Access is controlled through medical professionals, with approval aligned closely to US and EU indications but slower adoption of newer entrants.